MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) will highlight its pipeline of novel obesity and metabolic therapies in a fireside chat at the Life Sciences Virtual Investor Forum on June 24, 2026 at 10:30 am ET, a live, interactive event co-hosted by Zacks Small Cap Research.
Positive
- None.
Negative
- None.
News Market Reaction – MTVA
In the Jun 17 session, MTVA gained 3.64%, reflecting a moderate positive market reaction. Argus tracked a trough of -14.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | ADA obesity data | Positive | -11.3% | Shared new DA-1726 obesity and metabolic data from ADA 2026 sessions. |
| Jun 04 | Conference preview | Neutral | -8.6% | Announced upcoming Emerging Growth Conference presentation on obesity pipeline. |
| May 27 | Phase 1 update | Positive | +12.5% | Reported higher-dose Phase 1 DA-1726 results with significant weight loss signals. |
| May 20 | Peer-reviewed data | Positive | +47.9% | Highlighted publication supporting vanoglipel’s anti-fibrotic and metabolic potential in MASH. |
| May 18 | ADA poster plans | Neutral | +0.0% | Announced acceptance of three late-breaking abstracts for ADA 2026 presentations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong reactions to substantive clinical and mechanistic data (e.g., DA-1726 and vanoglipel updates) while conference and presentation announcements alone have sometimes coincided with negative or flat moves. Price responses have alternated between sharp rallies and selloffs, indicating event-specific rather than consistently directional behavior.
Over the past month, MetaVia has focused on its obesity and MASH pipeline, repeatedly highlighting DA-1726 and vanoglipel. On May 18, it announced upcoming ADA 2026 posters. This was followed by an 8-K on May 27 detailing Phase 1 DA-1726 data, and a separate peer-reviewed vanoglipel publication on May 20. Early June brought additional ADA data and multiple conference updates. Today’s investor forum appearance continues this pattern of active scientific and investor engagement around the cardiometabolic franchise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast will also be made available after the conclusion of the forum.
It is recommended that investors pre-register using this link and run the online system check to expedite participation and receive event updates.
MetaVia will be available for one-on-one meetings; investors may register using this link. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum-302803076.html
SOURCE MetaVia Inc.